NCT05038150 - Study of SGN1 in Patients With Advanced Solid Tumor | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 16, 2023

Primary Completion Date

January 18, 2028

Study Completion Date

August 31, 2028

Conditions

Advanced Solid Tumor

Interventions

DRUG

SGN1

The study drug, SGN1, will be administered as an IV infusion through a dedicated line catheter over 2 hours, which unit dose strength is 0.9-2.0×109 cfu /vial.

Trial Locations (8)

45267

SUSPENDED

University of Cincinnati Cancer Center, Cincinnati

48201

WITHDRAWN

Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit

85234

SUSPENDED

Banner MD Anderson Cancer Center, Gilbert

92868

SUSPENDED

Health Chao Family Comprehensive Cancer Center, Orange

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200233

RECRUITING

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai

511495

RECRUITING

Guangdong Clifford Hospital, Guangzhou

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu